ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1881

In Radiographic Axial Spondyloarthritis, Bridging Syndesmophytes Increase Risk of Facet Joint Ankylosis Development on the Same Vertebral Level While Facet Joint Ankylosis Does Not Increase Risk of Same Level Syndesmophytes Development

Rosalinde Stal1, Alexandre Sepriano2, Floris van Gaalen3, Xenofon Baraliakos4, Rosaline van den Berg1, Monique Reijnierse1, Juergen Braun5, Robert Landewé6 and Désirée van der Heijde1, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Center, Portela Loures, Portugal, 3Leiden University Medical Center (LUMC), Leiden, Netherlands, 4Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, 5Rheumazentrum Ruhrgebiet and Ruhr-University, 44649 Herne, Germany, 6Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands

Meeting: ACR Convergence 2020

Keywords: Ankylosing spondylitis (AS), Computed tomography (CT), spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: In radiographic axial spondyloarthritis (r-axSpA), spinal damage manifests as syndesmophytes and facet joint ankylosis (FJA). Whether there is an order in which lesion develops first is unknown.

Methods: Data were used from the Sensitive Imaging in Ankylosing Spondylitis (SIAS) cohort from Leiden and Herne. Inclusion criteria were: clinical r-axSpA diagnosis, ≥1 inflammatory lesion on spinal Magnetic Resonance Imaging (MRI), ≥1 and ≤18 syndesmophytes on conventional radiography of lateral cervical and lumbar spine, and fulfillment of the modified New York criteria. Patients underwent low-dose Computed Tomography (ldCT) at baseline and two-years. LdCT images were scored independently by two trained readers. Vertebrae were scored according to the Computed Tomography Syndesmophyte Score (CTSS) for presence and size of syndesmophytes; facet joints were scored as not-ankylosed and ankylosed. Analyses were performed on the vertebral unit (VU) level and using individual-reader data (Figure). Two hypotheses were tested: 1) presence of bridging syndesmophyte(s) is associated with FJA on the same VU two years later, and 2) presence of FJA is associated with syndesmophyte(s) on the same VU two years later. Generalized Estimating Equations (GEE) models were used to take into account the correlations between VUs from the same patient and adjusting for reader to account for individual reader scores. Two models were tested per hypothesis using different outcomes. Model 1 uses the presence of syndesmophytes or FJA as outcome adjusting for the outcome at baseline. Model 2 uses development of new syndesmophytes or FJA at two years plus an increase in the number of syndesmophytes or FJA.

Results: In total, 50 patients were included (mean age 49, 84% male, 82% HLA-B27+). At baseline, there was a higher percentage of bridging syndesmophytes (range: 10-60%) than FJA (range: 8-36%) considering all VUs and both readers (Figure). In both models, presence of bridging syndesmophytes was associated with development of FJA two years later (OR (95%CI) Model 1: 3.35 (2.18-5.14); Model 2: 2.23 (1.19-4.16)) while presence of FJA at baseline did not have a statistically significant association with development of syndesmophytes two years later (Table).

Conclusion: The data showed a higher occurrence of bridging syndesmophytes than FJA at baseline and showed  significantly increased odds to develop FJA when bridging syndesmophyte(s) are present on the same VU two years prior. This mechanism did not hold true for the other direction. These results cautiously imply that in our study population with advanced r-axSpA bridging syndesmophytes precede FJA, rather than FJA preceding syndesmophytes.

Figure: Percentage of occurrence of syndesmophytes and facet joint ankylosis per vertebral unit and per reader at baseline. Figure displaying percentages of patients with a bridging syndesmophyte and with facet joint ankylosis at baseline, per reader. The image on the left illustrates the vertebral unit level (VU) at which analyses were performed. Seven VUs are illustrated in dashed boxes as example. Synd, syndesmophyte; FJA, facet joint ankylosis; BL, baseline.

Table: Results of the GEE analyses of the two hypotheses Model 1 was adjusted for the outcome at baseline and both models were adjusted for the reader level, not shown in the table. Statistically significant odds ratios are presented in bold. FJA, facet joint ankylosis; BL, baseline; FU, follow-up


Disclosure: R. Stal, None; A. Sepriano, NOVARTIS, 1, UCB, 1; F. van Gaalen, Reuma Nederland, 1, Stichting vrienden van Sole Mio, 1, MSD, 1, Abbvie, 1, Novartis, 1; X. Baraliakos, AbbVie, 2, 5, 8, Novartis, 2, 5, 8, Celgene, 5, 8, Chugai, 5, 8, Pfizer, 5, 8, UCB, 5, 8, BMS, 5, 8, Merck, 5, 8, Galapagos, 5; R. van den Berg, None; M. Reijnierse, None; J. Braun, AbbVie (Abbott), 1, Amgen, 1, 2, 3, BMS, 1, 2, 3, Boehringer Ingelheim, 1, 2, 3, Celgene, 1, 2, 3, Celltrion, 1, 2, 3, Centocor, 1, 2, 3, Chugai, 1, 2, 3, Medac, 1, 2, 3, MSD (Schering-Plough), 1, 2, 3, Mundipharma, 1, 2, 3, Novartis, 1, 2, 3, Pfizer (Wyeth), 1, 2, 3, Roche, 2, Sanofi-Aventis, 1, 2, 3, UCB, 1, 2, 3, Eli Lilly, 1, 2, 3, EBEWE Pharma, 5, 8; R. Landewé, AbbVie, 2, 5, 8, AstraZeneca, 5, Bristol-Myers Squibb, 5, 8, Eli Lilly, 5, Galapagos, 5, Novartis, 5, Pfizer Inc, 2, 5, 8, UCB, 2, 5, 8, GlaxoSmithKline, 5, Janssen, 2, 5, 8, Merck, 5, 8, Rheumatology Consultancy BV, 1, Ablynx, 5, Amgen, 2, 5, 8, Celgene, 5, Gilead, 5, Novo Nordisk, 5, Roche, 2, 5, 8, Schering, 2, 5, 8, TiGenix, 5; D. van der Heijde, AbbVie, 5, Bristol-Myers Squibb, 5, Cyxone, 5, Galapagos NV, 5, Gilead Sciences, Inc., 5, GlaxoSmithKline, 5, Eli Lilly, 5, Novartis, 5, Pfizer, 5, UCB Pharma, 5, Amgen Inc., 5, Astellas, 5, AstraZeneca, 5, Boehringer Ingelheim, 5, Celgene, 5, Daiichi-Sankyo, 5, Janssen, 5, Merck, 5, Regeneron, 5, Roche, 5, Sanofi, 5, Takeda, 5, Imaging Rheumatology bv, 3, Eisai, 5.

To cite this abstract in AMA style:

Stal R, Sepriano A, van Gaalen F, Baraliakos X, van den Berg R, Reijnierse M, Braun J, Landewé R, van der Heijde D. In Radiographic Axial Spondyloarthritis, Bridging Syndesmophytes Increase Risk of Facet Joint Ankylosis Development on the Same Vertebral Level While Facet Joint Ankylosis Does Not Increase Risk of Same Level Syndesmophytes Development [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/in-radiographic-axial-spondyloarthritis-bridging-syndesmophytes-increase-risk-of-facet-joint-ankylosis-development-on-the-same-vertebral-level-while-facet-joint-ankylosis-does-not-increase-risk-of-sa/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-radiographic-axial-spondyloarthritis-bridging-syndesmophytes-increase-risk-of-facet-joint-ankylosis-development-on-the-same-vertebral-level-while-facet-joint-ankylosis-does-not-increase-risk-of-sa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology